CME FOR THE YEAR 2020

S.NO DATE SPEAKER TOPIC
1.18-01-2020DR. A. RAMACHANDRANKEY TAKE WAYS FROM CAROLINA TRIAL: SU POINT OF VIEW
2.20-01-2020DR. A. RAMACHANDRANLATEST GUIDELINES ON DIABETES MANAGEMENT: WHAT DOES IT MEAN IN CLINICAL PRACTICE?
3.25-01-2020DR. A. RAMACHANDRANBASAL INSULIN INITIATION AND TITRATION – PATIENT CENTERED APPROACH IN INDIAN SETTINGS
4.08-02-2020DR. A. RAMACHANDRANEFFICACY OF DPP4i: THE TEST OF TIME
5.11-02-2020DR. A. RAMACHANDRANHYPOGLYCAEMIA AND GLYCAEMIC VARIABILITY THE LURKING SHARKS
6.13-02-2020PROF. LESZEK CZUPRYNIAKMEAL TIME MASTERS: INTERNATIONAL PERSPECTIVE – TREAT to TARGET WITH INSULINS IN T2DM: WHAT, WHEN & WHY?
7.14-02-2020DR. A. RAMACHANDRANDIABETIC HEART DISEASE PERSONALIZED THERAPY
8.20-02-2020DR. ARUN RAGHAVANINSULIN INTENSIFICATION OPTION TO CONTROL POSTPRANDIAL

CME FOR THE YEAR 2019

S.NO DATE SPEAKER TOPIC
1. 12-03-19DR. NANDITHA ARUNACHIEVING GLYCEMIC CONTROL - EVOLVING NEW PRANDIAL INSULIN ANALOGUES
2.01-05-19DR. A. RAMACHANDRANEMPRISE STUDY IMPLICATIONS TO PRACTICE
3.06-05-193M FIRM TO ALL NURSESCLEANING DISINFECTION & STERILIZATION
4.07-05-19DR. NANDITHA ARUNACHIEVING OPTIMAL GLYCEMIC CONTROL -EVOLVING ROLE OF PRANDIAL INSULINS
5.11-05-19DR. NANDITHA ARUNCLINICAL EXPERIENCE WITH GLA - 300- A CASE BASED DISCUSSION
6.11-05-19MR. VIJAY - BIOCON PHARMABASICS OF DIABETES COMPLICATION & INSULIN TECHNIQUES
7.12-05-19DR. A. RAMACHANDRANSEETTING THE CONTEXT - MODERATOR
8.23-05-19DR. NANDITHA ARUNLINKING THE DOTS WITH GLP – 1RAs: T2DM, CVD AND OTHER COMORBIDITIES
9.24-05-19DR. A. RAMACHANDRANCARMELINA TRIAL – EVIDENCE ON CV AND HEART FAILURE SAFETY WITH LINAGLIPTIN
10.29-05-19DR. ARUN RAGHAVANPRESENT DAY APPROACH TO CV MORTALITY REDUCTION IN T2DM
11.09-07-19DR. A. RAMACHANDRANCILICAL APPROCH TO CARDIO – RENAL SYNDROME IN T2DM
12.09-08-19DR. NANDITHA ARUNMULTI – DISCIPLINARY MANAGEMENT OF OBESITY
13.16-08-19DR. ARUN RAGHAVANGLP- 1 RA: STRIVING TOWARDS AHOLOSTIC MANAGEMENT OF T2DM
14.22-08-19DIETICIAN PRESENTATION
MS. MUMTAJ
MS. CHRISTINE

MS. MUTHUMARI
MS. PURNIMA
– PROTEIN IN OUR DIALY DIET
– ROLE OF CAFFEINE IN YOUR DAILY DIET / INTERMITTENT FASTIN
– SUGAR & SUGAR PRODUCTS, VEGAN DIET
– GLUTEN INTOLERANCE
15.28-08-19DR. ARUN RAGHAVANVERIFYING THE STATUS OF EARLY GLYCEMIC CONTROL IN T2DM
16.13-09-19DR. NANDITHA ARUNACHIEVING OPTIMAL GLYCEMIC CONTROL- EVOLVING ROLE OF PRANDIAL INSULINS
17.18-11-19DR. ARUN RAGHAVANSGLT2 - I AND YOU: NOVEL EMPAGLIFLOZIN REGIMENS FOR HOLISTIC CARDIOVASCULAR AND GLYCAEMIA CONTROL
18.11-12-19DR. SANTHOSH JEYARAJ


DR. LAVANYA
INITIATION OF PREMIXED INSULIN

CURRENT STATUS OF SGLT2I IN T2DM & CLINICAL EVIDENCE OF REMOGLIFLOXIN

CME FOR THE YEAR 2018

S.NO DATE SPEAKER TOPIC
1.21-01-18DR. A. RAMACHANDRANDAPAGLIFLOZIN- ROLE IN TREATMENT OPTIMIZATION
2.28-01-18DR. A. RAMACHANDRANLET US MEET BASAGLAR – A NEW TAKE ON INSULIN GLARGINE
3.01-03-18DR. PRAGNADIABETIC FOOT ULCER WITH CELLULITIS
4.01-03-18DR. GIRIDHARMATURITY ONSET OF DM OF THE YOUNG
5.20-03-18DR. ARUN RAGHAVANCOMBINATION THERAPY: Right from the start?
6.06-04-18DR. ARUN RAGHAVANSIMPLIFYING INSULIN THERAPY FOR THE INDIAN PATIENT
7.12-04-18MR. ANANDBASIC LIFE SUPPORT TRAINING CLASS BY CFILS TO ALL DOCTORS
8.19-04-18DR. KISHOREDIABETIC NEPHROPATHY
9.19-04-18DR. LAVANYACPD - FIBRO CALCULOUS PANCREATIC DIABETES
10.19-04-18DR. ARUN RAGHAVANEMPOWERING CARDIO-METABOLIC OUTCOMES IN T2DM: LESSONS POST EMPA-REG OUT COME
11.04-06-18DR. NANDITHA ARUNCOMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN: HERALDING AN ERA OF 360 MANAGEMENT OF T2D
12.04-06-18DR. ARUN RAGHAVANEMPOWERING CARDIOMETABOLIC OUTCOMES IN T2DM: LESSONS POST EMPA-REG OUTCOME’’
13.09-06-18DR. MOHAMMED ZAIDGLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF TYPE 2 DM
14.09-06-18DR. SANTHOSH JEYARAJROLE OF PREMIX ANALOG IN THE MANAGEMENT OF DM
15.10-06-18DR. A. RAMACHANDRANCASE FROM CLINIC: A YOUNG OBESE FEMALE DIABETES PATIENTS
16.20-06-18MR. VIVEKANANDANEBULIZATION & INHALATION TECHNIQUES
17.23-06-18DR. A. RAMACHANDRANEMPAGLIFLOZIN/LINAGLIPTIN FDC: A LEAP TOWARDS HOLOSTIC T2D MANAGEMENT
18.12-07-18DR. VISHANTHMETOBOLIC SYNDROME
19.12-07-18DR. SHANMUGA PRIYADIABETES & PREGNANCY
20.18-07-18DR. ARUN RAGHAVANFROM LEAD TO LEADER – HbA1c TO HbA1CV
21.21-07-18DR. A. RAMACHANDRANDIABETES TODAY: PUTTING EVIDENCE INTO PRACTICE
22.27-07-18DR. NANDITHA ARUNEVOLVING TREATMENT OPTIONS FOR PATIENTS WITH TYPE 2 DIABETES: STRIKING THE RIGHT BALANCE WITH NEWER INSULIN CO- FORMULATION
23.28-07-18DR. A. RAMACHANDRAN
DAWNING THE SPLENDOUR OF CARDIOPROTECTION IN DIABETES
24.02-08-18DR. K. V. ARUNPERIODONTAL DISEASE & DIABETES – BIDIRECTIONAL RELATIONSHIP
25.02-08-18DR. P.D. MADAN KUMARORAL CASE FOR DIABETES PATIENT – RECENT CONCEPTS
26.04-08-18DR. A. RAMACHANDRANCOMPARING SECOND GENERATION BASAL INSULINS : A SPOTLIGHT ON THE BRIGHT STUDY
27.10-08-18DR. A. RAMACHANDRANINSULINS HAVE BECOME PATIENT FRIENDLY: MAKING TIMELY INSULIN INITIATION A REALITY
28.17-08-18DR. ARUN RAGHAVANI AM RISKING MY PATIENTS BY DELAYING INSULINIZATION
29.26-09-18DR. ARUN RAGHAVANWE LOOK FORWARD TO YOUR ESTEEMED PRESENCE AND PARTICIPATION!
30.11-10-18DR. NANDITHA ARUNCOMPARING SECOND GENERATION BASAL INSULINS : A SPOTLIGHT ON THE BRIGHT STUDY
31.21-10-18DR. A. RAMACHANDRANM. HEALTH: EMERGENCE OF NEW SCIENCE FOR DIABETES CARE AND PREVENTION
32.26-10-18DR. A. RAMACHANDRANCLINICAL IMPACT OF INITIATING INSULIN EARLY- ARE WE JUSTIFIED IN THE DELAY
33.11-11-18DR. ARUN RAGHAVANBASAL INSULIN CIRCLE
34.15-11-18DR. SANTHOSH JEYARAJLOGICAL CHOICE OF OAD: EMPHASIS ON GLIPTINS
35.19-11-18DR. A. RAMACHANDRANCV AND RENAL CO-MORBIDITIES WITH DIABETES: ELEPHANTS IN THE ROOM
36.28-11-18
DR. NANDITHA ARUNSTENO – A TALE TO TELL
37.09-12-18DR. ARUN RAGHAVANINSULIN INITIATION IN T2DM PATIENTS INADEQUATELY CONTROLLED ON OADs
38.14-12-18DR. NANDITHA ARUNPRESENT DAY APPROACH TO CV MORTALITY REDUCTION IN T2DM
39.28-12-18DR. NANDITHA ARUNINSTRIDE 1 AND 2 SAFETY AND EFFICACY OF BIOCON INSULIN OTHER REFERENCE GLARGINE

CME FOR THE YEAR 2017

S.NO DATE SPEAKER TOPIC
1.02-03-17MS. LANVANYA & MS. LAGNAROLE OF OILS & NUTS IN ONE’S DIET
2.20-04-17MS. GIFTAFRUITS & VEGETABLES
3.11-05-17MS. SATHYA NURSES & COMMUNICATION
4.11-05-17MS. ABIRAMYNURSING SERVICE & HOLISTIC APPROACH
5.11-05-17MR. ANANDA VOICE OF LEAD-NURSES DAY THEME 2017
6.06-08-17DR. NANDITHA ARUNPREVENTION OF DIABETES - AN UPDATE
7.20-08-17DR. A. RAMACHANDRANDIABETES 360: EXPERTS VIEW ON MANAGING DIABETES COMPLICATIONS
8.07-09-17MS. NITHYASHRINUTRITIONAL SUPPORT IN YOUNG CHILDREN & TYPE 1 DM
9.20-09-17DR. ARUN RAGHAVANBASAL OPTIMIZATION WITH GLP-I ANALOGUE
10.23-09-17DR. A. RAMACHANDRANINDIAN PATIENT OF T2DM: WHAT DOES EVIDENCE MEAN TO CLINICAL PRACTICE?
11.21-10-17DR. HENRI FROM FINLANDSLEEP DISORDER OF DIABETES
12.21-10-17DR. SANTHOSH JEYARAJASK THE EXPERT-OVERWEIGHT OR MAJORITY-RIGHT PATIENT FOR SGLT2i
13.16-11-17DR. VAIBHAV CASE PRESENTATION – TYPE 1 DM & HTN
14.16-11-17DR. BHAMACASE PRESENTATION – DIABETIC FOOT INFECTION
15.22-12-17DR. A. RAMACHANDRANCLINICAL IMPACT OF INITIATING INSULIN EARLY
16.22-12-17DR. ARUN RAGHAVANINITIATING INSULIN THERAPY: CLINICAL BENEFITS OF NEW INSULIN CO -FORMULATION
17.23-12-17DR. ARUN RAGHAVANEMERGING ROLE OF GLP1 ANALOQUSE IN T2DM: CARDIOVASCULAR AND RENAL OUTCOMES

CME FOR THE YEAR 2016

S.NO DATE SPEAKER TOPIC
1.25-01-16DR. PETER LINMETABOLIC STATE IN INDIAN TYPE 2 DIABETES
2.28-07-16DR. CHANDRASEKARANRENAL SPECIFIC NUTRITION
3.20-02-16DR. NANDITHA ARUNCANAGLIFLOXIN: PLACE IN THERAPY FOR INDIAN DIABETICS
4.23-02-16DR. NANDITHA ARUNIMPROVING METABOLIC STATE IN TYPE 2 DIABETES WITH SGLT2i
5.28-02-16DR. ARUN RAGHAVANIMPROVING METABOLIC STATE IN TYPE 2 DIABETES WITH SGLT2i
6.03-12-16DR. NANDITHA ARUNOVERCOMING CHALLENGES IN HYPERGLYCEMIC MANAGEMENT
7.22-04-16DR. NANDITHA ARUNTRULICITY LAUNCH
8.05-07-16DR. ARUN RAGHAVANADVANCING DIABETES CARE WITH GLP-1 RECEPTOR AGONISTS
9.01-12-16Dr. A. RAMACHANDRANRESOLVING HBA1C PARADOX IN MANAGEMENT OF TYPE 2 DIABETES
10.23-01-16Dr. A. RAMACHANDRANCAN WE CHANGE THE HISTORY OF TYPE 2 DIABETES
11.30-01-16Dr. A. RAMACHANDRANSGLT2I – NEW PARADIGM IN DIABETES
12.02-07-16Dr. A. RAMACHANDRANASIAN INDIANS - ARE WE DIFFERENT?
13.03-03-16Dr. A. RAMACHANDRANTRULICITY LAUNCH MEETING
14.15-05-16Dr. A. RAMACHANDRANCARDIOVASCULAR RISK MANAGEMENT IN DIABETES

CME FOR THE YEAR 2015

S.NO DATE SPEAKER TOPIC
1. 02-12-15DR. G. MANOHARAN, PLASTIC SURGEONDIABETIC FOOT ULCER
2.19-03-15DR. NIVIENDIABETIC RETINOPATHY
3.04-02-15DR. RAM JAGANATHANROUTINE PREDICTION OF TYPE 2 DIABETES
4.04-02-15DR. SELVAMPREVENTION OF TYPE 2 DIABETES
5.04-06-15DR. UMA MAHESHGLP ANALOGUES IN TYPE 2 DIABETES
6.04-06-15DR. SANTHOSH JAYARAJDPP4 INHIBITORS IN TYPE 2 DIABETES
7.23-06-15
MARY CATHERINOVERVIEW OF PROJECTS IMPLEMENTATION
8.13-08-15DR. GIRISHROLE OF PLASTIC SURGEON IN DIABETES
9.20-08-15DR. T. M.BA LAKRISHNANMICROVASCULAR RECONSTRUCTION IN REVASCULARISED DIABETIC FOOT
10.20-06-15DR. NANDITHA ARUNWHAT AFTER METFORMIN : CANAGLIPTOSIS
11.21-06-15DR. NANDITHA ARUNARE WESTERN GUIDELINES FOR DIABETES & DYSLIPIDEMIA HELPING OUR PATIENTS?
12.26-06-15DR. NANDITHA ARUNEMERGING ROLE OF THE KIDNEY AS A TARGET OF THERAPY
13.15-07-15DR. NANDITHA ARUNGLYCEMIC VARIABILITY
14.20-06-15DR. NANDITHA ARUNWHAT AFTER METFORMIN : CANAGLIPTOSIS
15.21-06-15DR. NANDITHA ARUNARE WESTERN GUIDELINES FOR DIABETES & DYSLIPIDEMIA HELPING OUR PATIENTS?
16.26-06-15DR. NANDITHA ARUNEMERGING ROLE OF THE KIDNEY AS A TARGET OF THERAPY
17.15-07-15DR. NANDITHA ARUNGLYCEMIC VARIABILITY

CME FOR THE YEAR 2014

S.NO DATE SPEAKER TOPIC
1.20-03-14Dr. V. B. NARAYANA MURTHYSCOPE AND DEATH OF PLASTIC SURGERY IN PREVENTION OF DIABETIC FOOT ULCERS
2.04-01-14Dr. ARAVINDAN SELVARAJDIABETIC PERIARTHRITIS IS A SURGICAL DISEASE
3.08-05-14Dr. ARAVINDAN SELVARAJGLYCAEMIC CONTROL IN ICU'S
4.31-07-14Dr. LATHA DULIPRINGHOSTEOPOROSIS, FRACTURES & BEYOND
5.21-08-14Dr. PRITHIKA CHARYNEUROLOGICAL MANIFESTATIONS IN DIABETES
6.25-09-14Prof. M. MADHAVANCURRENT CONCEPTS ON THE USE OF ORAL HYPOGLYCEMIC AGENT
7.18-04-14Dr. S. SUBRAMANIANPNEUMOCOCCAL VACCINATION IN SPECIAL POPULATION
8.16-10-14Dr. PANEERSELVAMINTERESTING CARE STUDIES IN DIABETES